To further evaluate the potential application of EV‐NID1 as a biomarker for HCC detection, the circulating EVs obtained from non‐HCC control subjects and HCC patients with early and late stage disease were validated prior to the analysis of NID1 level (Figure S11, Supporting Information). This evidence concerns the gene NID1 and hepatocellular carcinoma.